Results 91 to 100 of about 70,663 (209)
TGF-β-responsive CAR-T cells promote anti-tumor immune function. [PDF]
, 2018 A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-β) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant.
Chang, ZeNan L +4 more
core +1 more source
Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]
, 2016 Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios +4 more
core +3 more sources
Molecular Therapy: Methods & Clinical DevelopmentRegulatory T cells (Tregs) are promising cellular therapies to induce immune tolerance in organ transplantation and autoimmune disease. The success of chimeric antigen receptor (CAR) T cell therapy for cancer has sparked interest in using CARs to ...
Russell W. Cochrane +8 more
doaj +1 more source
Chimeric antigen receptors that trigger phagocytosis
eLife, 2018 Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity and suggests that applying CAR strategies to other immune cell lineages may
Meghan A Morrissey +6 more
doaj +1 more source
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle [PDF]
, 2013 Adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells showed spectacular efficacy in the treatment of leukemia in recent early phase trials.
Andreas A. Hombach, Hinrich Abken
core +2 more sources
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Journal of Hematology & Oncology, 2018 Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years.
Yixin Zou, Wei Xu, Jianyong Li
doaj +1 more source
Molecular Therapy: Oncolytics, 2019 Chimeric antigen receptor (CAR) is a hybrid molecule consisting of an antigen-binding domain and a signal transduction domain. The artificial T cells expressing CAR (CAR-T cells) are expected to be a useful tool for treatment of various diseases, such as
Jun-ichi Nunoya +3 more
doaj +1 more source
A homing receptor-IgG chimera as a probe for adhesive ligands of lymph node high endothelial venules. [PDF]
, 1990 The binding of lymphocytes to high endothelial venules (HEV) within peripheral lymph nodes (pln) is thought to be mediated by a lectinlike adhesion molecule termed the pln homing receptor (pln HR). The cloning and sequencing of cDNAs encoding both murine
Fennie, C +5 more
core
Protocol for generating human CAR-engineered macrophages by Vpx-containing lentivirus
STAR ProtocolsSummary: Human-derived macrophages are notoriously difficult to infect with HIV-1-based lentiviruses, posing a limitation to the advancement of chimeric antigen receptor macrophage (CAR-M) therapy.
Yun Gao +3 more
doaj +1 more source
Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors. [PDF]
, 2019 In 2017, the US Food and Drug Administration approved the first two novel cellular immunotherapies using synthetic, engineered receptors known as chimeric antigen receptors (CARs), tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta ...
Baybutt, Trevor R. +3 more
core +1 more source